<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01621750</url>
  </required_header>
  <id_info>
    <org_study_id>300-08</org_study_id>
    <nct_id>NCT01621750</nct_id>
  </id_info>
  <brief_title>Bioequivalence Study of Clopidogrel Tablets 300 mg Under Fasting Conditions</brief_title>
  <official_title>An Open Label, Balanced, Randomized, Two Treatment, Two Sequence, Two Period, Single-dose, Crossover Oral Bioequivalence Study of Clopidogrel Bisulfate 300 mg Tablets of Dr. Reddy's Laboratories Ltd., India and Plavix® (Clopidogrel Bisulfate) 300 mg Tablets Under Fasting Conditions</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Dr. Reddy's Laboratories Limited</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Dr. Reddy's Laboratories Limited</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To compare the bioavailability and characterize the pharmacokinetic profile of the Sponsor's&#xD;
      formulation (Clopidogrel Bisulfate 300 mg Tablets) with respect to the reference formulation&#xD;
      (Plavix® 300 mg tablets) in healthy, adult, human, male subjects under fasting conditions and&#xD;
      to assess the bioequivalence.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      An open label, balanced, randomized, two treatment, two sequence, two period, single-dose,&#xD;
      crossover oral bioequivalence study of Clopidogrel Bisulfate 300 mg Tablets of Dr. Reddy's&#xD;
      Laboratories Ltd., India and Plavix® (Clopidogrel Bisulfate) 300 mg Tablets of Bristol-Myers&#xD;
      Squibb/Sanofi pharmaceuticals partnership Bridgewater, NJ 0880750086441, USA, in healthy,&#xD;
      adult, human male subjects under fasting conditions.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>August 2008</start_date>
  <completion_date type="Actual">September 2008</completion_date>
  <primary_completion_date type="Actual">September 2008</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Area under curve(AUC)</measure>
    <time_frame>at pre-dose 0.25, 0.50, 0.75, 1.00, 1.25, 1.50, 1.75, 2.00, 2.25, 2.50, 3.00, 4.00, 6.00, 8.00, 12.00, 16.00, 20.00, 24.00, 36.00 and 48.00 hours post dose</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">68</enrollment>
  <condition>Fasting</condition>
  <arm_group>
    <arm_group_label>Clopidogrel</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Clopidogrel tablets 300 mg of Dr. Reddy's Laboratories Limited</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Plavix</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Clopidogrel Tablet 300 mg</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Clopidogrel</intervention_name>
    <description>Clopidogrel Tablets 300 mg</description>
    <arm_group_label>Clopidogrel</arm_group_label>
    <arm_group_label>Plavix</arm_group_label>
    <other_name>Plavix</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Healthy adult human male volunteers between 18 and 55 years of age (both inclusive)&#xD;
             living in and around Ahmedabad city of western part of India.&#xD;
&#xD;
          -  Having a Body Mass Index (BMI) between 18.5 and 24.9 (both inclusive), calculated as&#xD;
             weight in kg/height in m2.&#xD;
&#xD;
          -  Not having any significant diseases or clinically significant abnormal findings during&#xD;
             screening, medical history, clinical examination, laboratory evaluations, 12-lead ECG&#xD;
             and X-ray chest (postero-anterior view) recordings.&#xD;
&#xD;
          -  Able to understand and comply with the study procedures, in the opinion of the&#xD;
             Principal investigator.&#xD;
&#xD;
          -  Able to give voluntary written consent for participation in the trial.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Known hypersensitivity or idiosyncratic reaction to Clopidogrel or any related drug.&#xD;
&#xD;
          -  History or presence of any disease or condition which might compromise the&#xD;
             haemopoietic, renal, hepatic, endocrine, pulmonary, central nervous, cardiovascular,&#xD;
             immunological, dermatological, gastrointestinal or any other body system.&#xD;
&#xD;
          -  Ingestion of any medication at any time in 14 days prior to the dosing of Period-I. In&#xD;
             any such case subject selection was at the discretion of the Principal Investigator.&#xD;
&#xD;
          -  Any history or presence of asthma (including aspirin induced asthma) or nasal polyp or&#xD;
             NSAID induced urticaria.&#xD;
&#xD;
          -  A recent history of alcoholism (less than 2 years) or daily consumption of moderate&#xD;
             (180 mL / day) alcohol use or consumption of alcohol within 48 hours prior to&#xD;
             receiving the study medicine.&#xD;
&#xD;
          -  The presence of clinically significant abnormal laboratory values including APTT and&#xD;
             PT during screening.&#xD;
&#xD;
          -  Consumption of grapefruit and/or grapefruit products within 48hrs prior to dosing.&#xD;
&#xD;
          -  Use of any recreational drugs or history of drug addiction or testing positive in&#xD;
             pre-study drug scans.&#xD;
&#xD;
          -  History of psychiatric disorders.&#xD;
&#xD;
          -  A history of difficulty in donating blood.&#xD;
&#xD;
          -  Donation of blood (1 unit or 350 mL) within 90 days prior to receiving the first dose&#xD;
             of IP.&#xD;
&#xD;
        Note: In case the blood loss was less than or equal to 200 mL; subject was enrolled 60 days&#xD;
        after blood donation.&#xD;
&#xD;
          -  Smokers, who smoked more than 10 cigarettes / day or inability to abstain from smoking&#xD;
             during the study.&#xD;
&#xD;
          -  A positive hepatitis screen including hepatitis B surface antigen, HCV antibodies.&#xD;
&#xD;
          -  A positive test result for HIV antibody and/or syphilis.&#xD;
&#xD;
          -  The receipt of an investigational product or participation in a drug research study&#xD;
             within a period of 90 days prior to the first dose of study medication. Elimination&#xD;
             half-life of the study drug was taken into consideration for inclusion of the subject&#xD;
             in the study.&#xD;
&#xD;
        Note: If subject had participated in a study in which blood loss was less than or equal to&#xD;
        200 mL, subject was dosed 60 days after the last sample of previous study.&#xD;
&#xD;
          -  An unusual diet, for whatever reason (e.g. low-sodium), for four weeks prior to&#xD;
             receiving the study medication and throughout the subjects' participation in the&#xD;
             study. In any such case subject selection was at the discretion of the Principal&#xD;
             Investigator.&#xD;
&#xD;
          -  Any history of peptic ulcer disease, which include gastric &amp; duodenal ulcer or any&#xD;
             other bleeding disorders.&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Dr. Yogesh Gulati, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Lambda Therapeutic Research Ltd.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Lambda Therapeutic Research Ltd</name>
      <address>
        <city>Ahmedabad</city>
        <state>Gujrat</state>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>India</country>
  </location_countries>
  <verification_date>August 2008</verification_date>
  <study_first_submitted>June 14, 2012</study_first_submitted>
  <study_first_submitted_qc>June 14, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 18, 2012</study_first_posted>
  <last_update_submitted>June 14, 2012</last_update_submitted>
  <last_update_submitted_qc>June 14, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 18, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Clopidogrel</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

